I
n patients with congenital heart disease, single ventricle heart defects have a high risk of mortality in the first year of life and often result in late complications developing during the staged palliative repair. 1 Although single ventricle reconstruction trials have sought to determine predictors of poor outcome at 3 years in patients with single ventricle physiology on the basis of initial shunt types (Norwood procedure) and the timing of stage 2 palliation, a longitudinal cohort study in patients with Fontan (stage 3 procedure) circulation has shown that the risk of death or cardiac transplantation during 12 years was closely associated with poorer ventricular function and lower exercise performance after staged surgical procedures, rather than the type of shunt connection or ventricular morphology.
increased risk of extracardiac comorbidities in patients with single systemic ventricles are thought to occur over time, little is known about the involvement of heart failure with preserved ejection fraction (HFpEF) in the progression to multiorgan systemic dysfunction. 1 The epidemiology and pathophysiology of HFpEF in patients with single ventricle physiology remain elusive, largely because of disease-specific heterogeneity and attribution of underlying genetic factors, as well as technical variations in surgical procedures that may impact the outcome. 6 To date, no definitive therapy has been shown to improve cardiac function under chronic volume or pressure overload that may predispose patients with HFpEF to a worse prognosis. 7 Stem cell therapy trials are ongoing in a variety of congenital heart diseases to investigate their favorable effects on cardiac performance and functional health status. 5 Our early phase 1/2 clinical trials using intracoronary administration of autologous cardiosphere-derived cells (CDCs) have shown reliable and safe results for the treatment of patients with single ventricle physiology. 8, 9 These clinical trials had the limitation that only a few study participants were enrolled as a longterm control arm because of ethical considerations. 10 As such, we conducted a retrospective cohort study to evaluate the therapeutic efficacy of CDC infusion in patients with single ventricle physiology at 2 years. Data from CDC-infused patients were integrated with that of a larger population who met the overarching criteria for inclusion and were treated by staged surgical palliation alone in the same study period as a comparative effective clinical research to yield previously unappreciated information.
Methods
The authors declare that all data relevant to this study are available within the article and its Online Data Supplement. The individuallevel data that support the findings of this study are available from the corresponding author on reasonable request and approval of the data management team.
Patient Population
The study protocols and the initial results of the TICAP phase 1 (Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology) and PERSEUS phase 2 (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) trials have been described previously. [8] [9] [10] A total of 280 patients with single ventricle lesions constitutively underwent staged palliations between January 5, 2011, and January 30, 2015 (first patient enrolled for the TICAP study to the last patient assigned for the PERSEUS study). Among the study participants, 112 patients were excluded because they underwent stage 1 palliative procedures (Online Figure I) . Forty-one patients were prospectively assigned to receive CDC infusions in the TICAP and PERSEUS trials. Medical records of 60 patients were obtained and analyzed as a control group who were eligible but were treated by staged palliation alone. The comparative arm was constitutively enrolled and included 7 control subjects, 20 single ventricle patients excluded for having nonhypoplastic left heart syndrome in the TICAP trial, 30 patients who were not able to participate in both trials because of the review process of the PERSEUS study protocol, 2 patients who withdrew consent, and 1 patient because of endocarditis after surgery in the PERSEUS trial. No placebo infusions were given to control patients.
Study Design
The inclusion criteria were that patients were aged <6 years who were diagnosed with single ventricle lesions undergoing stage 2 or 3 palliation. Ventricular ejection fraction (EF) should be <60% during the initial screening through the final enrollment. This study was composed of 2 prospective and 1 retrospective cohort studies to investigate ongoing long-term follow-up after CDC infusion. The retrospective study protocol for collecting medical information from 
Novelty and Significance
What Is Known?
• Cardiosphere-derived cells (CDCs) provide short-term improvement in cardiac function through selected paracrine mechanisms to reverse ventricular remodeling and dysfunction.
• The risk/benefit aspects for intracoronary CDC infusion in patients with single ventricles have been investigated in a limited study population at 3 years of follow-up.
What New Information Does This Article Contribute?
• CDC infusion improves cardiac function at 2 years in patients with single ventricles treated by stage 2 or 3 palliation, regardless the phenotypic differences in the heart failure.
• Autologous CDC therapy is associated with reduced late failure, adverse events, and unplanned catheter intervention after shunt procedures in long term of follow-up.
• CDC application in patients with reduced ejection fraction and heart failure showed a significantly favorable impact on long-term survival.
In contrast with the large number of adult clinical trials, cell therapy trials for congenital heart disease and heart failure are limited. The appreciable ethical reasons and relatively rarity of heart failure with congenital heart malformations in stable clinical condition might have hindered the establishment and development of such clinical studies. This contemporary cohort study was conducted to enhance the number of control subjects with deep heart failure phenotyping to improve our understanding of therapeutic potential of CDCs in patients with single ventricles in long-term observation. The results of our study indicate that intracoronary CDC infusion is associated with lower risk of adverse events, and it reduces the incidence of late failure, as well as unplanned catheter intervention after staged palliative repair. In addition, CDCs improved event-free survival in patients with heart failure and reduced ejection fraction. These findings may accelerate trial progress and subsequent dissemination as standardized cell therapeutics for patients with congenital heart disease.
control patients was approved by the Ethics Committee of Okayama University and followed the guidelines on Clinical Research issued by the Ministry of Health, Labor, and Welfare, Japan. The study was conducted in accordance with the Declaration of Helsinki and by an opt-out method through the institutional website.
Follow-Up and End Points
The prespecified end point was the improvement of cardiac EF from baseline to 2 years of follow-up, as measured by echocardiography. Two-year clinical events analyzed included the composite of death of any cause and type, late failure, adverse events, and unplanned catheter intervention. Late failure was defined as late death (precluded death during the initial hospital stay), protein-losing enteropathy, stage 2 or 3 procedure takedown, stage 2 procedure patients who were not able to proceed to stage 3, Ross classification 3 or 4 at followup, or rehospitalization because of heart failure requiring additional medication or surgery. Adverse events included death, reoperation, ventricular arrhythmia (tachycardia and pacemaker implantation), thromboembolic events, atrioventricular valve regurgitation ≥moder-ate at follow-up, and rehospitalization because of heart failure. Blinded core laboratories assessed cardiac function measured by echocardiography, cardiac magnetic resonance imaging (cMRI), and ventriculography. For patients who died or underwent additional surgery or catheter-based reintervention, the primary outcome measure was obtained from the most recent cardiac imaging study immediately before the adverse event. For long-term outcome analysis, patients and investigators were unblinded. However, data acquisition and categorization of events were performed by an independent data manager and an event review committee who were unware of the group assignment.
Heart Failure Classification
Cardiac function was analyzed by 2-dimensional and color Doppler examinations and stored digitally for offline analysis by 2 pediatric cardiologists who were blinded to the group assignment. Enddiastolic volume and end-systolic volume were obtained from the dominant ventricle by the monoplane-modified Simpson method through a transverse apical 4-chamber view as described previously. 8 In this cotemporaneous cohort study, both control and CDC-treated patients with HFpEF were categorized according to the presence of heart failure symptoms and 50%≤EF<60% measured by echocardiography, whereas heart failure with reduced EF (HFrEF) was defined as <50%. cMRI was additionally used to assess the 3-month results of the TICAP and PERSEUS studies. EF measured by cMRI was calculated based on the quantification of single ventricle volume through short-axis cine images and was categorized as 40% to <50% for HFpEF, whereas HFrEF was defined as <40%. A subgroup of the cardiac function measured by both imaging modalities was tested by linear regression analysis.
Statistical Analysis
Because no previous cell therapy trials in single ventricle lesions have reported long-term evaluation of mortality and adverse events, clinical outcome measures in this study were descriptive and exploratory with no statistical hypothesis based on an estimated power calculation. Continuous variables are presented as the means and SD if normally distributed. Comparisons between groups were made by Student t tests, and changes from baseline within groups were evaluated by paired t tests. If normality could not be established, differences between groups were tested using nonparametric Mann-Whitney U tests, and changes from baseline within groups were tested by nonparametric Wilcoxon signed-rank tests. Categorical variables were expressed as the number and percentage of observations and were analyzed with Fisher exact tests. Clinical outcome was assessed by Kaplan-Meier analyses, and log-rank tests were applied to determine whether the distributions of time to the earliest event of death, late failure, adverse events, and catheter intervention during all available follow-ups differed between groups. The assumption of proportional hazards with respect to the clinical outcome after stage 2, 3, or combined stages was assessed by plotting the log-minus-log function over time. The model was adjusted for all the variables that were associated with an adverse clinical outcome in the crude analysis. Univariate regression analysis was performed to identify variables predictive of improvement in ventricular function. Nonlinearly associated variables were adjusted for stepwise selection for multivariate analysis. Univariate and multivariate stepwise Cox proportional hazard regression models were applied to assess the independent competing risks and hazard ratios (HRs) associated with the occurrence of adverse events. For comparison of 2 different categorical independent variables on the time interaction term within groups, 2-way ANOVA was used. All statistical tests reported were 2-sided, and values of P<0.05 were considered to be significant. All analyses were performed using the SPSS software (version 24; IBM Corporation, Armonk, NY). The statistical methods applied were critically reviewed and supervised by a medical biostatistician who had no role in data collection and interpretation.
Results
Our previous results from the TICAP phase 1 and PERSEUS phase 2 prospective studies in 48 patients have shown that intracoronary administration of CDCs may lead to global and regional functional improvement at 3 months by a significant reduction in cardiac mechanical efficiency (Ea/Ees) compared with patients treated by standard palliation alone (Online Figures II and III; Online Table I ). The major study limitations of these trials are the lack of a control arm for long-term comparison, and that a mixed study population undergoing different stages of surgical repair, either stage 2 or 3 procedures, were enrolled during the initial registry. Therefore, this cohort study was sought to determine the stage-specific clinical outcome after intracoronary CDC transfer in patients with single ventricles by direct comparison with the subjects treated by surgical palliation alone in larger population.
Baseline Characteristics
Between January 5, 2011, and January 30, 2015, 41 patients with single ventricle physiology were enrolled in either TICAP or PERSEUS trials to receive CDC infusions, and 60 control subjects, including 7 patients prospectively allocated as controls in the TICAP study, were treated using staged surgical repair without cell delivery. Of 101 patients, 39 subjects (39%) underwent stage 2 and 62 subjects (61%) underwent stage 3 palliation. Baseline characteristics of the CDC-treated patients and controls in each stage did not differ significantly (Table 1; Online Table II) .
Anatomic diagnosis, previous surgery received, and values of brain natriuretic peptide were similar within the groups.
Response to CDC Infusion at 2 Years After Stage 2 or 3 Palliation
Cardiac function was assessed by echocardiography in 60 controls and 41 CDC-treated patients 1 month after staged palliation and compared with that at 2 years after treatment. The absolute changes in EF from baseline to 2-year follow-up showed significant improvements in CDC-treated patients compared with controls after each staged procedure ( Figure 1A ; stage 2: +8.4±10.0% versus +1.6±6.4%, P=0.03; stage 3: +7.9±7.5% versus −1.1±5.5%, P<0.001). Somatic growth and heart failure status were both markedly improved in CDC-treated patients compared with controls in both palliative stages ( Figure 1D and 1F). A significant reduction in brain natriuretic peptide levels was found in patients treated with CDCs after the stage 3 procedure (P=0.035; Figure 1E) . A 2-year follow-up of clinical events Data are expressed as n (%) or the mean±SD. Between-group differences in characteristics were analyzed with Fisher exact tests for categorical variables and Student t tests for normally distributed continuous variables. Data that were not normally distributed were analyzed with Mann-Whitney U tests. There were no significant baseline differences among the study groups at a significance level of 0.05. AVV indicates atrioventricular valve; AVVR, atrioventricular valve regurgitation; BNP, brain natriuretic peptide; BT, Blalock-Taussig; CAVV, common atrioventricular valve; CDC, cardiosphere-derived cell; CoA, coarctation of the aorta; DILV, double inlet left ventricle; DKS, Damus-Kaye-Stansel; DORV, double outlet right ventricle; HLHS, hypoplastic left heart syndrome; LV, left ventricle; PA, pulmonary artery; PA/IVS, pulmonary atresia with intact ventricular septum; and TAPVC, total anomalous pulmonary venous connection.
was completed in 101 patients (100%). The median follow-up time was 38 months (interquartile range, 31-60 months). CDC infusions in combined stage 2 and 3 procedures significantly favored the prespecified end points, including late failure, adverse events, and catheter intervention, as shown by the HRs: 0.387 (95% CI, 0.167-0.9; P=0.028), 0.4 (95% CI, 0.19-0.844; P=0.016), and 0.333 (95% CI, 0.144-0.768; P=0.01), respectively ( Figure 2C ). In the patients who underwent stage 3 palliation, CDC infusion was shown to be significantly associated with a lower hazard of adverse events (HR, 0.253; 95% CI, 0.083-0.771; P=0.016; Figure 2B ).
Patient Outcome
A total of 12 deaths (11.9%) occurred during the followup, including 9 (survival, 85%) in controls and 3 (survival, 92%) in the CDC-treated group (Table 2 ). There were no significant differences in all-cause mortality between the groups (P=0.351); however, patients who received CDC infusion showed significantly reduced incidences of late failure (P=0.016), adverse events (P=0.013), and unplanned catheter intervention (P=0.009) compared with controls (Table 2) . Although event-free survival at 2 years was significantly higher in CDC-treated patients compared with controls (100% versus 86.7%; P=0.02), overall survival did not differ between the 2 groups in all available follow-up data (log-rank P=0.225; Figure 3A) . None of the patients in this study received heart transplantation. Corresponding to the results shown in Table 2 , patients treated by CDCs had significantly lower incidences of late failure (log-rank P=0.022), adverse events (log-rank P=0.013), and catheter intervention (log-rank P=0.005) over time compared with controls ( Figure 3B through 3D) .
Competing Risks for Adverse Events and Factors Associated With Functional Improvement
The prognostic relevance of adverse events was analyzed using univariate and multivariate Cox proportional hazard models. The strongest association was identified in patients who had a higher heart failure status, as defined by the New York University Pediatric Heart Failure Index ≥11, for which the risk was increased >2.6-fold (P=0.036; Table 3 ). Most importantly, CDC infusion in patients with single ventricles was significantly associated with a lower HR to experience adverse events after staged palliation (HR, 0.411; 95% CI, 0.179-0.942; P=0.036; Table 3 ). In addition, multivariate regression analysis revealed baseline EF to have the greatest prognostic impact on functional improvement after CDC infusion (P=0.015; Online Table III) .
Outcomes in Patients According to the Subtypes of Heart Failure After CDC Application
Because there is still a poor understanding of how the grade of heart failure affects the clinical outcome after CDC treatment in patients with single ventricles, we sought to determine longitudinal changes in cardiac function and outcomes in patients with HFpEF and HFrEF. In the short-term results of TICAP and PERSEUS studies, cardiac function measured by cMRI and echocardiography in patients with HFpEF receiving CDCs did not differ from controls (Online Figure IVA  through IVF) . Although the therapeutic efficacy could only be observed in patients with HFrEF at 3 months, there was a significant improvement in the circumferential global strain in both patients with HFpEF (P=0.006) and HFrEF (P=0.02) 3 months after CDC infusion compared with controls (Online Figure IVG) . In the long-term study, baseline characteristics and medications of the patients did not differ between CDCtreated patients and controls in each categorized heart failure group (Online Table IV Figure 4A ). The improvement in cardiac function could be seen by a significant reduction in cardiac systolic volumes ( Figure 4B ). The absolute changes of weight for age corrected by z scores and brain natriuretic peptide were greater only in the HFpEF group (weight for age: +1.3±1.1 versus −0.5±1.5, P<0.001; brain natriuretic peptide: −19.2±17.3 versus −0.2±17.7 pg/mL, P=0.005; Figure 4D and 4E). Compared with controls, CDC treatment significantly decreased the heart failure status, assessed by New York University Pediatric Heart Failure Index and the Ross classification, in both groups ( Figure 4F and 4G) .
During follow-up, 3 CDC-treated patients with HFpEF died after 2 years. The overall survival in the HFpEF group was 75% for patients receiving CDCs versus 85% for controls (log-rank P=0.679; Figure 5A ), whereas no patients died in the HFrEF group treated by CDC infusion, as shown by a significantly lower all-cause mortality during follow-up (log-rank P=0.038; Figure 5B ). The improved outcome in patients with HFrEF receiving CDCs was further characterized by significantly reduced incidences of late failure (log-rank P=0.028) and adverse events (log-rank P=0.046), compared with those treated by staged palliation alone ( Figure 5D and 5F). In the HFpEF cohort study, the benefits of CDC infusion for preventing late complications were not statistically evident during follow-up ( Figure 5C and 5E).
Mechanisms of CDC-Mediated Cardiac Repair in Congenital Heart Failure
The pathophysiology of HFpEF in congenital heart disease, including single ventricles, is yet to be fully elucidated. A pulmonary artery banding was created to model right heart failure in rats to investigate the underlying mechanisms involved in cardiac repair followed by CDC therapy. At 4 weeks after banding, a pressure-volume study was performed to define HFpEF based on an EF ≥40%. Compared with medium-treated rats, animals with HFpEF that received CDC Table V ). In medium-treated animals, cardiac function deterioration was manifested by a decrease in EF (P=0.006) with elevated end-diastolic pressure (P=0.004) and myocardial stiffness measured by the slope of the end-diastolic pressurevolume relationship (P=0.002), whereas these parameters were relatively preserved in CDC-treated rats with HFpEF. In the HFrEF rat study, medium-treated animals showed significant ventricular dilatation in end-systole (P=0.03). The therapeutic effects of CDCs appeared more obvious in HFrEF rats, as shown by a significantly greater improvement in EF (43.3±5.7% at 1 month versus 27.3±7.7% at baseline; P<0.001) that coincided with a marked reduction in end-systolic volume (P=0.03) and an increase in cardiac output and stroke volume compared with the baseline (P<0.001; Online Table VI) .
Histological evaluation revealed that right ventricular hypertrophy was observed 4 weeks after banding with remarkable fibrotic remodeling of the myocardium that was significantly attenuated by CDC infusion 4 weeks after treatment in both HFpEF and HFrEF rats (P<0.001; Online Figure  V) . Compared with sham-operated rats, transcripts of collagen depositions and inflammatory cytokines were upregulated in both HFpEF and HFrEF animals. The gene expressions of Col3A1 (collagen type 3) and IL-6 (interleukin-6) were markedly suppressed by CDC infusion in both groups. Interestingly, Col1A2 (collagen type 1), MMP2 (matrix metalloproteinase type 2), and NPPA (atrial natriuretic peptide) expressions remained unchanged in HFrEF rats compared with a significant reduction seen in HFpEF rats (Online Figure VI) .
Discussion
The disproportionate share of mortality and morbidity in patients with single ventricles among congenital heart diseases may limit long-term observational studies to relatively small sample sizes with biased populations toward survivors at each stage. 11, 12 In this complex context, variability in the underlying genetic causes may exist in the study population, and heterogeneity in the types of single ventricle may also influence maladaptive responses after surgical reconstruction. 13 Our results addressed several unanswered questions with regard to stage-specific responses to CDC therapy with potent clinical implications. Heterogeneity in the study population resulted from structural differences and phenotypic diversity in heart failure in patient and animal studies. A significant feature of this integrated cohort study was its evaluation of the clinical outcome, including all-cause mortality and late complications, by direct comparison with controls treated by standard surgical procedures alone. As such, the limitations of this study are its observational nature, which included neither prospective data collection nor randomization.
The anatomic and morphological subtypes of single ventricles are critical determinants of the outcome. Predictors for functional improvement after CDC therapy were analyzed, and it was revealed that hypoplastic left heart syndrome or heterotaxy syndrome were not risk factors for a poor outcome (Online Table III ). However, disease variations in complex structural heart disease might exist and may not have been detected in the relatively small sample size of this study, thus affecting its practical therapeutic efficacy. Increasing the number of specific univentricular heart diseases, such as hypoplastic left heart syndrome, across multicenters using trial registry rather than recruiting a diverse range of single ventricles in a single center may address these limitations.
Another issue of the early TICAP and PERSEUS studies was the initial results obtained from the mixed study population treated by different staged palliations.
14 Direct comparisons within the stratified staged procedure in this cohort study may enable us to elucidate the CDC-mediated functional Tumor formation 0 0 APCA indicates aortopulmonary collateral artery; AVVR, atrioventricular valve regurgitation; BCPS, bidirectional cavopulmonary shunt; CDC, cardiospherederived cell; PA, pulmonary artery; and TCPC, total cavopulmonary connection.
benefits and clinical outcome in a similar systemic circulation by ventricular remodeling after surgical reconstruction. In patients who underwent stage 2 palliation, survivors who were able to proceed to the stage 3 procedure in the CDC-treated group and controls at a 2-year follow-up did not differ (80% versus 90%; P=0.586). The functional improvement after 1 year in stage 2 patients may be affected by the interstage variance of patients proceeding to stage 3 palliation, leading to differential responses with altered relaxation properties and ventricular filling, as well as increased afterload in the absence of pulsatile flow in Fontan circulation. 15 The heterogeneous population in this study was further explored by functional subtypes of heart failure. The results of predictor analysis suggested that cardiac function measurement at baseline may provide insight into the therapeutic responsiveness and implications of CDC treatment in single ventricles (Online Table III ). In all available follow-up data, all-cause mortality in control patients with HFrEF increased after stage palliation, but not in those treated by CDCs, whereas overall survival declined after >1 year in the HFpEF group ( Figure 5 ). This differential 1-year outcome between HFpEF and HFrEF was supported by the fact that lower cardiac function at baseline was associated with an increased risk of death or transplantation. 2 In the HFpEF group, death occurred in 3 CDC-treated and 3 control patients. Among them, sudden cardiac death occurred in 1 case for each treatment. Death attributed to progression of heart failure occurred in 2 controls, whereas 2 patients who underwent stage 2 palliation died 2 years after CDC infusion because of circulatory failure caused by conduit obstruction after the stage 3 procedure. In the absence of compelling outcome data to support CDC therapy in patients with HFpEF, our finding of all-cause mortality in patients with HFpEF by 2 years is consistent with the favorable effects of CDC treatment, as seen by improved regional myocardial strain at 3 months resulting in enhanced global cardiac function at 2 years (Online Figure IV; Figure 4 ). 16 The role of HFpEF in adult heart disease has been extensively studied; however, its pathogenic and prognostic significance in single ventricles remains largely unknown. 17, 18 No definitive therapy has been shown to have favorable effects on Figure 4 . Response to cardiospherederived cell (CDC) infusion in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The study population was stratified by HFpEF (EF ≥50%) or HFrEF (<50%) based on EF measured by echocardiography at the baseline. Changes in cardiac function (A-C), somatic growth (D), and heart failure status (E-G) from baseline to 2 years of follow-up are shown. At 2 years, cardiac function (A and B) and heart failure index scores (F and G) were significantly improved in both patients with HFpEF and HFrEF receiving CDC infusions (red bars) compared with controls (black bars). Data are expressed as the means (SD). Between-group comparisons were performed using Student t tests. BSA indicates body surface area; and NYUPHFI, New York University Pediatric Heart Failure Index. mortality in outcome trials in patients with HFpEF. 7 Although medication trials in adults to reduce all-cause mortality by testing an angiotensin-converting enzyme inhibitor or mineralocorticoid receptor antagonist have shown moderately positive outcomes in a retrospectively defined subgroup or by an adjusted analysis, no treatments have been shown to affect mortality in HFpEF patients with congenital heart disease. 19, 20 The difficulty in treatment may be attributed to distinct pathophysiological mechanisms that develop the heart failure into diverse HFpEF phenotypes. 21 A possible mechanism found in our animal studies was the involvement of myocardial fibrosis through extracellular matrix modification and inflammatory responses via IL-6. 22, 23 Our results are consistent with the facts that CDCs improved diastolic dysfunction by attenuating regional fibrosis and inflammatory infiltration in hypertrophic and ischemic myocardium. 24, 25 Whether resident fibroblasts or extracardiac progenitors were responsible for aberrant homeostatic control of collagen remains unknown. 26 Figure 5 . Comparison of freedom from death and late complications in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Event-free survival (A and B), late failure (C and D), and adverse events (E and F) were compared between cardiosphere-derived cell (CDC)-treated patients (red lines) and controls (black lines) in HFpEF and HFrEF subpopulations, respectively. Log-rank tests were applied for statistical analyses.
expression of Col3A1 in HFpEF compared with that in HFrEF without CDC treatment suggests that there might be a different degree of cardiac fibrosis composition through procollagen synthesis and secretion between HFpEF and HFrEF groups (8.3±0.9 versus 4.4±0.7; P=0.008; Online Figure VI ). 22 Although we did not detect any specific configuration of cardiac fibrosis in both types of heart failure models, collagen metabolism, involving collagen degradation after cell therapy, might differ between these distinct heart failure phenotypes. 28 Recent advances in cMRI-derived T1 mapping may enable us to determine the composition of myocardial fibrosis, such as diffuse or focal depositions, in patients with single ventricles, as well as to monitor fractional changes after cell therapy in real time.
29,30

Limitations
As with all observational cohort studies, our results may be biased, confounding, and inferior to those obtained from randomized controlled trials. 31 This integrated comparative research was designed and conducted on the basis of the difficulty to recruit patients with rare congenital heart diseases and the inability to treat control subjects by standardized surgery alone for long-term observation as a hierarchical randomized controlled trials because of ethical considerations. Manufacturing CDCs should be conducted by institutional departments alongside tissue harvesting and subsequent cell transfer; this would limit the study to a single-center experience. Although the control data were obtained from patients treated by the usual palliative procedure during the same period as the TICAP and PERSEUS trials, the registry settings may have affected the results. The total sample size was not determined based on statistical power considerations. Subgroups for stage-specific and heart failure phenotype-dependent analyses were performed in small sample sizes, limiting their power to assess associations and the potential outcome. cMRI and catheter examinations were not performed in all control patients at 2 years of follow-up, to obtain myocardial strain analysis and pulmonary vascular function. These data may provide additional prognostic value for heart failure but could not be assessed in a portion of controls. 16, 32 Instead, echocardiography was used in this contemporaneous cohort study from baseline to follow-up to assess cardiac function without missing data for imputation. Along with the TICAP and PERSEUS protocols, we precluded patients with an EF ≥60%, limiting the sample size in patients with HFpEF as relatively small to assess causality. Findings of improved mortality in CDC-treated patients with HFrEF compared with controls were encouraging, but the observational period may be too short to infer the pragmatic effects of CDC treatment in the long term. Our results failed to determine the mechanisms involved in late death occurring in patients with HFpEF receiving CDCs. Extracardiac comorbidities that may drive ventricular dysfunction through circulatory failure should be taken into account in this complex pathophysiology.
Despite the fact that pressure overload may not directly recapitulate the systemic hemodynamics of single ventricular circulation, this experimental approach has been shown to assess reversible ventricular remodeling by attenuating myocardial fibrosis after stem cell injection in a porcine model of right heart failure. 33 The definition of HFpEF in animal studies was determined based on a cardiac function of ≥40%, as measured by a catheter, and may differ from cohort studies that stratified the borderline as 50% by echocardiography.
Conclusions
In this integrated cohort study, intracoronary delivery of CDCs significantly improved ventricular function and reduced the incidences of late failure, adverse events, and unplanned catheter intervention in patients with single ventricles that underwent stage 2 or 3 palliation at 2 years of follow-up. Patients treated with CDCs had a lower hazard for the magnitude of treatment effects on adverse events. Baseline cardiac function was an independent predictor of functional improvement after cell therapy. Although CDC infusion improved cardiac function and heart failure status in both patients with HFpEF and HFrEF, all-cause mortality and late complications were significantly reduced in HFrEF but not in HFpEF subjects receiving CDCs. Longer follow-up is underway to clarify the differential therapeutic responses underlying the phenotypic diversity in heart failure with single ventricle physiology.
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